Pds biotech announces presentation of data from nci-led triple combination phase 2 clinical trial in advanced, refractory hpv-positive cancers at asco 2022

77% of checkpoint inhibitor (cpi) refractory patients alive at median follow up of 12 months
PDSB Ratings Summary
PDSB Quant Ranking